|
 I
know I promised all of you a new trading idea on Friday. However, after
thinking a little more about it, I've decided to wait until Saturday
morning to send it out. I know for a lot of you a 40+ hour workweek
can make it tough to read and process one more thing late in the day on
a Friday. I'd rather introduce you to this company when you're relaxed
on Saturday...so you can prop your feet up and really immerse yourself
in the newsletter, as well as the short video. And believe me, this
is a stock worth making this little accommodation for - I think it deserves
everyone's
full
attention. See you Saturday morning. In the meantime...
 |
 |
BioCurex:
The Other Shoe Has Dropped |
|
 They
say when it rains it pours, but when it's good news, I guess that's a good
thing. Just two days after we heard from BioCurex (OTCBB:
BOCX) about early success with their rapid 'point of care' cancer
screening tests, we're now hearing from them about the big enchilada...the
lab-based version of their cancer detection test. Abbott Laboratories
(NYSE: ABT) has - for
the first time we're aware of - publicly presented successful use of
BioCurex's RECAF technology using Abbott's diagnostic instruments.
For
those of you who have been following the BioCurex/RECAF story closely,
you may immediately understand the magnitude of this news. For others,
let me catch you up with the condensed version of the tale.
RECAF
is a cancer marker, meaning it can pinpoint if or where there are cancerous
cells, and not show a 'positive' test result if there are no cancerous
cells. BioCurex has been developing the RECAF detection technology for
a few years now. The progress and results so far have been very promising,
so
much so that Abbott became a licensee for the test even though the
test is not yet completely ready for use. In fact, Abbott has been working
with BioCurex in an effort to get the test ready. (What does that
tell you?)
As
it became clear the RECAF test had merit, it was also realized the format
for doing the underlying lab work was not ideal - RECAF was originally
designed to use radioimmunoassay (radioactivity-based) to determine whether
or not cancerous cells were present. Most medical labs, however, have
started using chemiluminescent assays (light-based). In order to have
wide appeal, a major format change would have to take place...and it
did. (For more details on the assay issue and BioCurex's adaptation,
click here to go back to our October 25th, 2006 edition by clicking
here.)
 Abbott,
despite being a licensee as well as major supplier of the equipment used
in most diagnostic labs, had been fairly quiet on the topic, until now.
At this year's International Society for Oncodevelopmental Biology and
Medicine conference - going on now - Abbott Laboratories has
finally publicized what they've been doing with BioCurex's creation.
The
evidence comes in the form of two presentations at the conference. The
first
one explains how the chemiluminescent assay can and does distinguish
between cancerous and non-cancerous serum. The Abbott-built device scored
a 0.954 out of a possible 1.00, in terms of successfully identifying positive
and negative samples. The second presentation discusses the ideal kind
of tube to use for the purpose of performing a RECAF test in a diagnostic
lab. As it turns out, the 'best' collection device to use for RECAF testing
is also the most common kind. The full press release is at the bottom of
this newsletter.
Neither
Abbott nor BioCurex has specifically made the following points, but there
are some observations that immediately came to my mind as I went through
this news...
1)
This was Abbott doing the testing and presenting - not BioCurex.
2)
While BioCurex is a small cap, Abbott is a major name in the diagnostic
world...they own 1/3 of the diagnostics market.
3)
The test seems to work as far as I can see through my non-biotechnician
eyes. A score of 0.954 out of 1.00 is a grade of 95.4% to me...which
is outstanding when it comes to medical diagnostic metrics.
4)
The test can be performed by the vast majority of labs.
 Maybe
it's just me, but doesn't this address all of the major concerns the
market has had about BioCurex?
I have
to think this is a major leap towards monetization of the test. That's
not to say it'll be ready and on the market tomorrow morning, but it may
be sooner than anybody thinks.
As
for the stock, you know how these things work. The market tends to price
a stock at what it thinks it will be worth in the future - not what
it's worth now. As such, I think this could be one heck of a bullish
jolt. In fact, the rumors already did push the stock upward to some degree...that's
why we jumped on it back on September
4th. It's been rolling since then (and even before then), and
I suspect this news will put the pedal to metal. Wanna' get on for the
ride?
|
|
Titan
Global Knocks On Door Of New Highs |
|
 In
a blog
entry Wednesday I mentioned how Titan Global (OTCBB:
TTGL) looked like it had fallen back all it was going to, and was
starting to drop a few bullish hints. Specifically, a key Fibonacci retracement
line had been met, and we were starting to see higher highs and higher
lows again.
If
you were waiting for a second chance on TTGL, I really hope you
read yesterday's comments. Why? The stock is off to the races (again) today,
up quite firmly on good volume. In fact, it reached as high as $2.20 on
an intra-day basis. That $2.20 level is significant it seems; that's
where TTGL topped on September 6th as well. When and if that resistance
is breached, I won't be a bit surprised to see another major short-term
rally.
At
last look, this suggested idea is up more than 70% above our pick price
of $1.21. Don't forget though...our suggested target is still $3.00.
Anyway,
here's the BioCurex news...
|
Source:
BioCurex, Inc.
BioCurex
and Abbott Jointly Present RECAF Results at International Cancer Congress
RICHMOND, British
Columbia, September 20, 2007 -- BioCurex Inc. (OTCBB:
BOCX) -- today announced the acceptance of two presentations submitted
to the International Society for Oncodevelopmental Biology and Medicine
(ISOBM). The presentations document two RECAF studies involving joint initiatives
with the University of Munich, Germany and Abbott.
The first presentation
entitled "CHEMILUMINESCENT ASSAY (CIA) FOR THE RECEPTOR OF ALPHA FETOPROTEIN
(RECAF) TO SEPARATE CANCER FROM NORMAL SERA" demonstrates the results obtained
with the assay format used in several automated instruments including the
Abbott ArchitectTM. 68 breast, gastric and other types of cancers were
compared to 52 normal patients and the AUC1 scoring obtained was 0.954
(a perfect discrimination between cancer and normal samples has a score
of 1.0). Similar results were independently obtained in our Licensee's
facility for prostate cancer samples.
The second study
was done in collaboration with our Licensee and the University of Munich
to determine the best type of specimen collecting tube for RECAF testing
in a clinical laboratory environment. There is an extensive variety of
blood collecting tubes available. These are vacuum tubes that contain different
combinations of chemicals intended to accelerate clotting in various ways,
prevent clotting, separate the clot from the serum, etc. Some of them are
not compatible with certain assays and therefore it is always necessary
before the commercialization of a serum test to find out which tubes are
chemically compatible. The results presented indicate that the RECAF assay
is compatible with the most commonly used serum collection tube types.
Ricardo Moro,
President and CEO stated: "These presentations to the ISOBM validate our
joint efforts to develop the RECAF assay in the chemoluminescence format
used by high throughput automated instruments. These results correlate
with those in previous presentations and provide additional support for
the effectiveness of the RECAF technology. This presentation will, no doubt,
trigger a positive response from the scientific community and demonstrate
to our shareholders that we are steadily progressing toward the commercialization
of the technology. Developing the foundations of a test that has the potential
to significantly change the way we diagnose cancer takes time and focus.
The team effort with this major diagnostic company has resulted in very
significant progress - part of which will be presented at this Meeting.
We are getting closer and closer to the commercialization of a cancer test
that has the potential to be used for screening patients in much the same
way a blood sugar or cholesterol reading is requested as part of a routine
blood test. This is extremely valuable, both from the medical as well as
the commercial point of view.
(1 AUC is the
Area Under the Curve of a statistic test called Receiver Operating Characteristic
or ROC. For more information go to: http://en.wikipedia.org/wiki/Receiver_operating_characteristic.)
About The International
Society of Oncodevelopmental Biology and Medicine (ISOBM):
The ISOBM originated
in the early 1970's from the International Research Group for Carcinoembryonic
Proteins. Since then the society has grown to cover wider aspects of research
in oncodevelopmental / oncofetal biology. The society also organizes a
series of Antibody Workshops. These workshops provide a practical focus
on tumor markers in all types of cancer.
About our Licensee:
BioCurex has signed
a licensing agreement with Abbott Laboratories for BioCurex's RECAFTM Cancer
technology as outlined in a joint press release dated March 29, 2005. The
release noted that the cancer marker RECAFTM has emerged as a potential
biomarker that may be useful in the development of new cancer diagnostics
tests. (http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0030.htm)
About BioCurex:
BioCurex, Inc.
is a biotechnology company that is developing products based on patented/proprietary
technology in the areas of cancer diagnosis, imaging and therapy. The technology
identifies a cancer marker known as RECAFtm, which is found on malignant
cells from a variety of cancer types but is absent in most normal or benign
cells.
To read more about
the Company, please visit the News section in our web site (www.biocurex.com).
Note: The Company
has not authorized the release of this information in any form that contravenes
the Communication Act and will not be responsible for unsolicited massive
distribution of this material by e-mail or facsimile by unauthorized parties.
Statements in this press release, which are not historical facts, are "forward-looking
statements'' within the meaning given to that term in the Private Securities
Litigation Reform Act of 1995. The Company intends that such forward-looking
statements be subject to the safe harbors created thereby. Since these
statements involve risks and uncertainties and are subject to change at
any time, the Company's actual results could differ materially from expected
results.
Contact:
Terry Johnston
BioCurex, Inc.
Tel: (866) 884-8669
or +1 604-267-3041 |
| |
|
|
| |
 |
Got comments, questions or suggestions?
Send 'em on over: Email
the Editor
If you wish to send a written request
or inquiry, please send it to our physical address:
TGR Group, LLC
4653 Carmel Mtn Rd Suite 308 #402
San Diego, CA 92130 |
|
|
| CEL-SCI
Announces Progress For Multi-Purpose Vaccine Adjuvant |
| With
all the talk about CEL-SCI's (AMEX:
CVM) Multikine cancer treatment, it's easy to forget they're also working
on a vaccine adjuvant platform that could ultimately be effective against
several types of infections....including hepatitis B, malaria, herpes,
and encephalitis, just to name a few. The name of the adjuvant is CEL-1000.
If it rings a bell, it may be because this small cap biotech company's
CEL-1000 technology really came to light in early 2006 when it was realized
it could be an effective tool in the war against the bird flu.
On
Monday, CEL-SCI updated the market on CEL-1000's status by releasing details
about research done using the vaccine adjuvant against the hepatitis B
virus. In a lab setting, it was found to increase the antibody signal in
a mouse by 40% by the 28th day of observation. The study also determined
what may be the ideal time of dosage, and degree of dosage.
The
'bigger picture' implication is simple enough...CEL-1000 continues to gain
validity as a broad vaccine adjuvant. As more research refines how CEL-1000
can and should be used, the potential appeal to the market expands.
For
the details of the news, click
here.
As
for CVM shares, the patient went into a critical status this summer, but
appears to have stabilized over the last month.
It
finally looked like CVM might get something going in April. Then between
May and August, we saw shares slide from a peak of $1.08 to a low of $0.57.
Since hitting $0.57 though, we've started to see the waters being tested
again. Specifically, we're not seeing a string of lower lows anymore. In
fact, the 50 day line was tested as resistance three times over the last
three weeks. So, clearly somebody is interested.
As
for whether or not I think the worst is over, let's just say I'm keeping
a close eye on CVM for that possibility. The downtrend has stopped and
a wedge has formed. The wedge will have to close up sometime, and force
this chart out of its confines. That could be good or bad (bullish or bearish),
but if it's bullish I want to be ready. For me, the 50 day line may be
the make-or-break point.
To
see a chart, click
here. |
|
|
|
